Last reviewed · How we verify
Regadenoson central - peripheral
Regadenoson central - peripheral acts as an adenosine A2A receptor agonist.
Regadenoson central - peripheral acts as an adenosine A2A receptor agonist. Used for Nuclear stress test for coronary artery disease.
At a glance
| Generic name | Regadenoson central - peripheral |
|---|---|
| Sponsor | Lokien van Nunen |
| Drug class | Adenosine receptor agonist |
| Target | A2A receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Regadenoson central - peripheral works by activating the adenosine A2A receptor, which leads to vasodilation and increased blood flow to the heart muscle. This allows for more accurate assessment of cardiac function during stress tests.
Approved indications
- Nuclear stress test for coronary artery disease
Common side effects
- Headache
- Flushing
- Nausea
- Dizziness
Key clinical trials
- Regadenoson and Adenosine (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Regadenoson central - peripheral CI brief — competitive landscape report
- Regadenoson central - peripheral updates RSS · CI watch RSS
- Lokien van Nunen portfolio CI